AUS
NZ
UK
CA
USA
IND
Highlights
- RC220 Phase 1 trial approved at two Hong Kong hospitals
- Expansion supports faster recruitment and regional relevance
- Broadening cardio-oncology footprint with international sites
Race Oncology (ASX:RAC) has announced key regulatory progress in its global clinical development strategy, with its RC220 Phase 1 trial receiving Human Research Ethics Committee (HREC) approvals at two prominent Hong Kong hospitals. This expansion underscores growing interest in the company’s cardio-oncology platform and advances its potential treatment combining RC220 with the chemotherapy agent doxorubicin.
RC220 is a next-generation formulation of bisantrene, a molecule developed to reduce cardiotoxicity commonly associated with traditional chemotherapeutic agents. The upcoming clinical trial, labelled RAC-010, aims to evaluate RC220’s safety, tolerability, and pharmacokinetics, both as a standalone treatment and in combination with doxorubicin. The company’s momentum follows earlier Australian site activations and now sees international expansion with strategic significance. As part of the broader innovation landscape among ASX healthcare stocks, RC220 underscores the growing potential for oncology breakthroughs led by Australian biotech firms.
Race Oncology’s inclusion in the ASX 200 share price index highlights its emerging role in the biotech investment landscape, supported by growing institutional and clinical interest.
The approved trial sites — Queen Mary Hospital (already sanctioned by Hong Kong’s Department of Health) and Prince of Wales Hospital (approval expected soon) — are expected to begin site activation between late July and mid-August. These facilities will help recruit eligible patients diagnosed with solid tumours, contributing to a broader and more diversified clinical dataset.
Three key considerations guided Race Oncology’s choice of Hong Kong for its expanded clinical footprint:
- Leading Clinical Investigators: The study will be led by prominent physicians in the region who see potential in RC220 for mitigating doxorubicin-induced heart damage.
- Accelerated Recruitment: By adding new trial sites, the company expects a faster enrolment process, boosting clinical progress.
- Regional Relevance: Hong Kong’s pharmaceutical regulatory environment and patient demographics add valuable data diversity for a treatment with global aspirations.
Patient screening will commence post-site activation, with candidates assessed under the care of participating clinicians. Details of the trial, including eligibility criteria, are available via clinicaltrials.gov.
Race Oncology’s strategy extends beyond Australia and Hong Kong, with plans to introduce additional trial sites in South Korea. These developments reinforce the company’s position as a key player in cardio-oncology innovation, with a growing international presence and strategic alignment in high-standard research jurisdictions.
With its global trial infrastructure taking shape, Race Oncology (RAC) is positioning itself for a transformative phase in clinical development.
